$OMER
OMEROS CORP

2023 Q2 Form 10-Q Financial Statement

#000155837023008814 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.26M $11.10M
YoY Change -19.12% 1.31%
% of Gross Profit
Research & Development $29.64M $24.61M
YoY Change 26.04% 2.17%
% of Gross Profit
Depreciation & Amortization $332.0K $186.0K
YoY Change 73.82% -33.09%
% of Gross Profit
Operating Expenses $29.64M $24.61M
YoY Change -20.83% 2.17%
Operating Profit -$40.90M -$35.71M
YoY Change 9.24% 1.9%
Interest Expense $7.932M $7.933M
YoY Change -260.99% 60.55%
% of Operating Profit
Other Income/Expense, Net $4.537M $3.963M
YoY Change 577.16% 703.85%
Pretax Income -$44.29M -$39.68M
YoY Change 6.23% 0.48%
Income Tax
% Of Pretax Income
Net Earnings -$37.30M -$33.70M
YoY Change 20.91% 2.09%
Net Earnings / Revenue
Basic Earnings Per Share -$0.59 -$0.54
Diluted Earnings Per Share -$0.59 -$0.54
COMMON SHARES
Basic Shares Outstanding 62.83M 62.83M
Diluted Shares Outstanding 62.84M 62.83M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $341.2M $371.5M
YoY Change 178.38% 161.21%
Cash & Equivalents $6.600M $3.800M
Short-Term Investments $334.6M $367.7M
Other Short-Term Assets $7.001M $6.708M
YoY Change -41.1% -12.0%
Inventory
Prepaid Expenses
Receivables $40.15M $38.67M
Other Receivables $124.0K $302.0K
Total Short-Term Assets $388.6M $417.0M
YoY Change 101.62% 98.38%
LONG-TERM ASSETS
Property, Plant & Equipment $22.01M $22.36M
YoY Change -12.15% -8.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.054M $1.054M
YoY Change 0.0% 0.0%
Total Long-Term Assets $138.9M $143.1M
YoY Change -9.19% -10.03%
TOTAL ASSETS
Total Short-Term Assets $388.6M $417.0M
Total Long-Term Assets $138.9M $143.1M
Total Assets $527.4M $560.1M
YoY Change 52.59% 51.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.552M $6.446M
YoY Change -12.17% -12.24%
Accrued Expenses $29.79M $30.82M
YoY Change 7.85% 29.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $99.51M $97.50M
YoY Change
Total Short-Term Liabilities $143.5M $139.2M
YoY Change 272.82% 296.94%
LONG-TERM LIABILITIES
Long-Term Debt $342.5M $344.3M
YoY Change 8.94% 9.67%
Other Long-Term Liabilities $20.92M $21.74M
YoY Change -17.91% -13.8%
Total Long-Term Liabilities $363.4M $366.0M
YoY Change 6.93% 7.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $143.5M $139.2M
Total Long-Term Liabilities $363.4M $366.0M
Total Liabilities $506.9M $505.2M
YoY Change 33.98% 35.01%
SHAREHOLDERS EQUITY
Retained Earnings -$706.7M -$669.4M
YoY Change -6.52%
Common Stock $727.2M $724.4M
YoY Change 1.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.51M $54.94M
YoY Change
Total Liabilities & Shareholders Equity $527.4M $560.1M
YoY Change 52.59% 51.69%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$37.30M -$33.70M
YoY Change 20.91% 2.09%
Depreciation, Depletion And Amortization $332.0K $186.0K
YoY Change 73.82% -33.09%
Cash From Operating Activities -$32.34M $174.5M
YoY Change 66.12% -1248.56%
INVESTING ACTIVITIES
Capital Expenditures $275.0K $0.00
YoY Change -366.99%
Acquisitions
YoY Change
Other Investing Activities $35.65M -$181.3M
YoY Change 43.5% 136.07%
Cash From Investing Activities $35.38M -$181.3M
YoY Change 42.98% 136.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -260.0K -388.0K
YoY Change 162.63% -340.99%
NET CHANGE
Cash From Operating Activities -32.34M 174.5M
Cash From Investing Activities 35.38M -181.3M
Cash From Financing Activities -260.0K -388.0K
Net Change In Cash 2.774M -7.180M
YoY Change -46.38% -92.18%
FREE CASH FLOW
Cash From Operating Activities -$32.34M $174.5M
Capital Expenditures $275.0K $0.00
Free Cash Flow -$32.62M $174.5M
YoY Change 68.42% -1248.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.09
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.10
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62828765
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62724775
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001285819
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62828765
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62828765
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.63
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.63
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-34475
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
OMEROS CORPORATION
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WA
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1663741
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
201 Elliott Avenue West
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98119
CY2023Q1 dei City Area Code
CityAreaCode
206
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
676-5000
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
OMER
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62828765
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3829000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11009000
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
367527000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
183909000
CY2023Q1 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
28940000
CY2022Q4 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
28797000
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
10033000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
213221000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6708000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6300000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
417037000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
443236000
CY2023Q1 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
119681000
CY2022Q4 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
123425000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21025000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21762000
CY2023Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1335000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1492000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1054000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1054000
CY2023Q1 us-gaap Assets
Assets
560132000
CY2022Q4 us-gaap Assets
Assets
590969000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6446000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5989000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30821000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30551000
CY2023Q1 us-gaap Senior Notes Current
SeniorNotesCurrent
94554000
CY2022Q4 us-gaap Senior Notes Current
SeniorNotesCurrent
94381000
CY2023Q1 omer Royalty Obligation Current
RoyaltyObligationCurrent
2943000
CY2022Q4 omer Royalty Obligation Current
RoyaltyObligationCurrent
1152000
CY2023Q1 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
4427000
CY2022Q4 omer Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
4310000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
139191000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
136383000
CY2023Q1 us-gaap Senior Long Term Notes
SeniorLongTermNotes
221209000
CY2022Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
220906000
CY2023Q1 omer Royalty Liabilities Non Current
RoyaltyLiabilitiesNonCurrent
123057000
CY2022Q4 omer Royalty Liabilities Non Current
RoyaltyLiabilitiesNonCurrent
125126000
CY2023Q1 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
21287000
CY2022Q4 omer Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
22426000
CY2023Q1 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
452000
CY2022Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
444000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62828765
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62828765
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
628000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
628000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
723726000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
720773000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-669418000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-635717000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
54936000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
85684000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
560132000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
590969000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24610000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24087000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11103000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10959000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-592000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
35713000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
35046000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-35713000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-35046000
CY2023Q1 us-gaap Interest Expense
InterestExpense
7933000
CY2022Q1 us-gaap Interest Expense
InterestExpense
4941000
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
3963000
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
493000
CY2023Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-39683000
CY2022Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-39494000
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
5982000
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
6483000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-33701000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-33011000
CY2023Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.63
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.63
CY2023Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.09
CY2022Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.10
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62828765
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62724775
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23780000
CY2022Q1 omer Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
414000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3892000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-33011000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-4925000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
85684000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2953000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-33701000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
54936000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-33701000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-33011000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2953000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3892000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
477000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
446000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
186000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
278000
CY2023Q1 omer Interest On Contract Royalty Asset
InterestOnContractRoyaltyAsset
3925000
CY2022Q1 omer Interest On Contract Royalty Asset
InterestOnContractRoyaltyAsset
4838000
CY2023Q1 omer Remeasurement Adjustment On Contract Royalty Asset
RemeasurementAdjustmentOnContractRoyaltyAsset
1677000
CY2022Q1 omer Remeasurement Adjustment On Contract Royalty Asset
RemeasurementAdjustmentOnContractRoyaltyAsset
2158000
CY2023Q1 omer Unrealized Accretion On Investments
UnrealizedAccretionOnInvestments
2316000
CY2022Q1 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
454000
CY2023Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-203188000
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-21900000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
582000
CY2021Q4 omer Percentage Of Royalty Receivable On Sale Of Product Rights
PercentageOfRoyaltyReceivableOnSaleOfProductRights
0.50
CY2023Q1 omer Increase Decrease In Contract Royalty Asset Current
IncreaseDecreaseInContractRoyaltyAssetCurrent
-9203000
CY2022Q1 omer Increase Decrease In Contract Royalty Asset Current
IncreaseDecreaseInContractRoyaltyAssetCurrent
-13831000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
733000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-15671000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
174539000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15193000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
523941000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
83013000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
342610000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
6200000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-181331000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-76813000
CY2023Q1 omer Principal Payments On Royalty Obligations
PrincipalPaymentsOnRoyaltyObligations
278000
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
110000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
253000
CY2022Q1 omer Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
414000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-388000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
161000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7180000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-91845000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11009000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100808000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3829000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8963000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
7933000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
5967000
CY2021Q4 omer Milestone Payment If Achieved Under Asset Purchase Agreement
MilestonePaymentIfAchievedUnderAssetPurchaseAgreement
200000000.0
CY2021Q4 omer Payment Due After Milestone Period
PaymentDueAfterMilestonePeriod
P30D
CY2021Q4 omer Milestone Period
MilestonePeriod
P4Y
CY2022Q4 omer Milestone Payment Receivable From Sale Of Royalty Under Asset Purchase Agreement
MilestonePaymentReceivableFromSaleOfRoyaltyUnderAssetPurchaseAgreement
200000000.0
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
371400000
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
10000000.0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-33700000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
174500000
CY2023Q1 omer Cash Proceeds From Milestone Payment
CashProceedsFromMilestonePayment
200000000.0
CY2023Q1 omer Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
150000000.0
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:12.25pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Use of Estimates </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include OMIDRIA contract royalty asset valuation, stock-based compensation expense, and accruals for clinical trials and manufacturing of drug product. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</p>
CY2022Q4 omer Percentage Of Royalty Receivable On Sale Of Product Rights
PercentageOfRoyaltyReceivableOnSaleOfProductRights
0.30
CY2022Q4 omer Milestone Payment Receivable From Sale Of Royalty Under Asset Purchase Agreement
MilestonePaymentReceivableFromSaleOfRoyaltyUnderAssetPurchaseAgreement
200000000.0
CY2021Q4 omer Percentage Of Reduction In Royalty Receivable Upon Breach Of Agreement Term
PercentageOfReductionInRoyaltyReceivableUponBreachOfAgreementTerm
0.10
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4871000
CY2021Q4 omer Milestone Payment If Achieved Under Asset Purchase Agreement
MilestonePaymentIfAchievedUnderAssetPurchaseAgreement
200000000.0
CY2021Q4 omer Percentage Of Royalty Receivable On Sale Of Product Rights
PercentageOfRoyaltyReceivableOnSaleOfProductRights
0.50
CY2022Q4 omer Percentage Of Royalty Receivable On Sale Of Product Rights
PercentageOfRoyaltyReceivableOnSaleOfProductRights
0.30
CY2022Q4 omer Milestone Payment Receivable From Sale Of Royalty Under Asset Purchase Agreement
MilestonePaymentReceivableFromSaleOfRoyaltyUnderAssetPurchaseAgreement
200000000.0
CY2022Q4 omer Percentage Of Royalty Receivable On Sale Of Product Rights
PercentageOfRoyaltyReceivableOnSaleOfProductRights
0.30
CY2023Q1 omer Percentage Of Interest Earned On Outstanding Contract Royalty Asset
PercentageOfInterestEarnedOnOutstandingContractRoyaltyAsset
0.110
CY2023Q1 omer Cash Proceeds From Milestone Payment
CashProceedsFromMilestonePayment
200000000.0
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17223451
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17340176
CY2023Q1 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
28940000
CY2022Q4 omer Contract Royalty Asset Current
ContractRoyaltyAssetCurrent
28797000
CY2023Q1 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
119681000
CY2022Q4 omer Contract Royalty Asset Noncurrent
ContractRoyaltyAssetNoncurrent
123425000
CY2023Q1 omer Contract Royalty Asset
ContractRoyaltyAsset
148621000
CY2022Q4 omer Contract Royalty Asset
ContractRoyaltyAsset
152222000
CY2023Q1 omer Royalty Receivables
RoyaltyReceivables
7600000
CY2022Q4 omer Royalty Receivables
RoyaltyReceivables
12966000
CY2023Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2131000
CY2023Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
302000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
255000
CY2022Q4 omer Milestone Payment Receivable
MilestonePaymentReceivable
200000000
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
10033000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
213221000
CY2023Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2100000
CY2023Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
10842000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
11040000
CY2023Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
9507000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
9548000
CY2023Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1335000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1492000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8778000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6665000
CY2023Q1 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
6486000
CY2022Q4 omer Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
5536000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4871000
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
3703000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
5172000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3686000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4425000
CY2023Q1 omer Accrued Contract Research Costs
AccruedContractResearchCosts
2630000
CY2022Q4 omer Accrued Contract Research Costs
AccruedContractResearchCosts
3209000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
667000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
673000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30821000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30551000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
3400000
CY2022Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
2200000
CY2023Q1 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
367527000
CY2023Q1 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
205000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
367732000
CY2023Q1 us-gaap Debt Securities Available For Sale And Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
368581000
CY2023Q1 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
205000
CY2023Q1 us-gaap Debt Securities Available For Sale And Held To Maturity Fair Value
DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue
368786000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
183909000
CY2022Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
22000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
183931000
CY2022Q4 us-gaap Debt Securities Available For Sale And Held To Maturity Amortized Cost After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
184963000
CY2022Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
22000
CY2022Q4 us-gaap Debt Securities Available For Sale And Held To Maturity Fair Value
DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue
184985000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3800000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11000000.0
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
320030000
CY2023Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
4267000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
315763000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
320030000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
4743000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
315287000
CY2023Q1 omer Cash Contractual Interest Expense On Royalty Obligation
CashContractualInterestExpenseOnRoyaltyObligation
3000000.0
CY2023Q1 omer Royalty Obligation Principal Payments Due Remainder Of Fiscal Year
RoyaltyObligationPrincipalPaymentsDueRemainderOfFiscalYear
874000
CY2023Q1 omer Royalty Obligation Interest Payments Due Remainder Of Fiscal Year
RoyaltyObligationInterestPaymentsDueRemainderOfFiscalYear
8876000
CY2023Q1 omer Royalty Obligation Payments Due Remainder Of Fiscal Year
RoyaltyObligationPaymentsDueRemainderOfFiscalYear
9750000
CY2023Q1 omer Royalty Obligation Principal Payments Due Next Twelve Months
RoyaltyObligationPrincipalPaymentsDueNextTwelveMonths
8576000
CY2023Q1 omer Royalty Obligation Interest Payments Due Next Twelve Months
RoyaltyObligationInterestPaymentsDueNextTwelveMonths
11424000
CY2023Q1 omer Royalty Obligation Payments Due Next Twelve Months
RoyaltyObligationPaymentsDueNextTwelveMonths
20000000
CY2023Q1 omer Royalty Obligation Principal Payments Due Year Two
RoyaltyObligationPrincipalPaymentsDueYearTwo
14641000
CY2023Q1 omer Royalty Obligation Interest Payments Due Year Two
RoyaltyObligationInterestPaymentsDueYearTwo
10359000
CY2023Q1 omer Royalty Obligation Payments Due Year Two
RoyaltyObligationPaymentsDueYearTwo
25000000
CY2023Q1 omer Royalty Obligation Principal Payments Due Year Three
RoyaltyObligationPrincipalPaymentsDueYearThree
16081000
CY2023Q1 omer Royalty Obligation Interest Payments Due Year Three
RoyaltyObligationInterestPaymentsDueYearThree
8919000
CY2023Q1 omer Royalty Obligation Payments Due Year Three
RoyaltyObligationPaymentsDueYearThree
25000000
CY2023Q1 omer Royalty Obligation Principal Payments Due Year Four
RoyaltyObligationPrincipalPaymentsDueYearFour
17664000
CY2023Q1 omer Royalty Obligation Interest Payments Due Year Four
RoyaltyObligationInterestPaymentsDueYearFour
7336000
CY2023Q1 omer Royalty Obligation Payments Due Year Four
RoyaltyObligationPaymentsDueYearFour
25000000
CY2023Q1 omer Royalty Obligation Principal Payments Due After Year Five
RoyaltyObligationPrincipalPaymentsDueAfterYearFive
68164000
CY2023Q1 omer Royalty Obligation Interest Payments Due After Year Five
RoyaltyObligationInterestPaymentsDueAfterYearFive
10586000
CY2023Q1 omer Royalty Obligation Payments Due After Year Five
RoyaltyObligationPaymentsDueAfterYearFive
78750000
CY2023Q1 omer Royalty Obligation Principal Payments Due
RoyaltyObligationPrincipalPaymentsDue
126000000
CY2023Q1 omer Royalty Obligation Interest Payments Due
RoyaltyObligationInterestPaymentsDue
57500000
CY2023Q1 omer Royalty Obligation Payments Due
RoyaltyObligationPaymentsDue
183500000
CY2023Q1 omer Number Of Options To Extend Lease Term
NumberOfOptionsToExtendLeaseTerm
2
CY2023Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1100000
CY2022Q1 omer Decrease In Right Of Use Asset Due To Early Operating Lease Termination
DecreaseInRightOfUseAssetDueToEarlyOperatingLeaseTermination
4700000
CY2022Q1 omer Decrease In Lease Liability Due To Early Operating Lease Termination
DecreaseInLeaseLiabilityDueToEarlyOperatingLeaseTermination
5200000
CY2022Q1 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
500000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1633000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1196000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
118000
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
197000
CY2023Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
51000
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
56000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
790000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
860000
CY2023Q1 us-gaap Sublease Income
SubleaseIncome
375000
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
491000
CY2023Q1 us-gaap Lease Cost
LeaseCost
2217000
CY2022Q1 us-gaap Lease Cost
LeaseCost
1818000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1780000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1803000
CY2023Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
152000
CY2022Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
253000
CY2023Q1 omer Long Term Purchase Commitment Termination Fee
LongTermPurchaseCommitmentTerminationFee
26100000
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
200000
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
23.00
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y6M
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
380000
CY2023Q1 omer Share Based Payment Arrangement Expense Continuing Operations
ShareBasedPaymentArrangementExpenseContinuingOperations
2994000
CY2022Q1 omer Share Based Payment Arrangement Expense Continuing Operations
ShareBasedPaymentArrangementExpenseContinuingOperations
3892000
CY2023Q1 omer Share Based Payment Arrangement Expense Discontinuing Operations
ShareBasedPaymentArrangementExpenseDiscontinuingOperations
-41000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2953000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3892000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13872973
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.02
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
38500
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.00
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
195052
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.78
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13716421
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.00
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M6D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2172000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
13342280
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.08
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y6M
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1982000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10142013
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.06

Files In Submission

Name View Source Status
omer-20230331_pre.xml Edgar Link unprocessable
omer-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001558370-23-008814-index-headers.html Edgar Link pending
0001558370-23-008814-index.html Edgar Link pending
0001558370-23-008814.txt Edgar Link pending
0001558370-23-008814-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
omer-20230331.xsd Edgar Link pending
omer-20230331x10q.htm Edgar Link pending
omer-20230331xex31d1.htm Edgar Link pending
omer-20230331xex31d2.htm Edgar Link pending
omer-20230331xex32d1.htm Edgar Link pending
omer-20230331xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
omer-20230331_def.xml Edgar Link unprocessable
omer-20230331_lab.xml Edgar Link unprocessable
omer-20230331x10q_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending